Fig. 10

The key genes and potential drugs vValidation. KGN cells were initially subjected to a 24-h pre-treatment with 10 μM testosterone, after which we assessed: (A) the mRNA levels of 5 diagnostic genes, (B) SA-β-Gal activity, (C) the protein expression levels of p16 and p21, and (D) Edu immunofluorescence staining. E The proliferation curves of KGN cells with and without 10 μM testosterone intervention, across a 5-day period. F The intracellular ceramides levels of KGN cells with or without 24-h 10 μM testosterone. G KGN cells, preconditioned with testosterone, were treated with a range of aspirin concentrations (0 μM, 10 μM, 20 μM, 40 μM) for 24 h, after which the protein levels of p16 and p21 were quantified. H The activity of SA-β-Gal, (I) Edu immunofluorescence staining, (J) cell proliferation rates, and (K) intracellular ceramide levels were additionally assessed in KGN cells treated with either 0 or 20 μM aspirin. * P < 0.05, ** P < 0.01, *** P < 0.001. ns, no statistically significant difference